CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...
Phase 3
Houston, Texas, United States and 18 other locations
will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...
Phase 1
Houston, Texas, United States and 20 other locations
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
Houston, Texas, United States and 36 other locations
with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...
Phase 3
Houston, Texas, United States and 121 other locations
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...
Phase 3
Houston, Texas, United States and 122 other locations
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...
Phase 4
Houston, Texas, United States and 35 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Houston, Texas, United States and 220 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Houston, Texas, United States and 230 other locations
) neo-antigen in subjects with relapsing multiple sclerosis (RMS)....
Phase 3
Houston, Texas, United States and 301 other locations
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple...
Phase 3
Houston, Texas, United States and 209 other locations
Clinical trials
Research sites
Resources
Legal